Table 6

Relationships between coregulator genes mRNA levels and clinical, pathological, and molecular parameters in ERα-positive breast tumors of 99 postmenopausal patients

CoactivatorsCorepressors
TIF2AIB1GCN5L2NCOR1MTA1L1
AgeNSaNSNSNSNS
 ≤7050b8.3 ± 5.4c3.7 ± 2.36.7 ± 5.45.8 ± 3.44.3 ± 2.1
 >70497.0 ± 3.33.4 ± 1.77.1 ± 5.35.4 ± 2.34.0 ± 1.8
Histological gradedNSNSNSNSNS
 I138.1 ± 3.82.7 ± 0.95.4 ± 1.86.1 ± 2.64.3 ± 1.6
 II648.0 ± 4.63.8 ± 2.37.2 ± 5.65.6 ± 2.64.1 ± 2.0
 III216.7 ± 4.53.3 ± 1.46.6 ± 5.85.3 ± 4.03.8 ± 1.6
Lymph node statusNSNSNSNSNS
 0168.1 ± 6.73.2 ± 1.67.6 ± 5.95.0 ± 2.23.6 ± 1.6
 1–3567.5 ± 3.53.4 ± 2.25.4 ± 6.96.0 ± 2.94.3 ± 2.1
 >3277.9 ± 4.74.0 ± 1.94.9 ± 6.85.3 ± 3.34.1 ± 1.8
Macroscopic tumor sizeeNSNSNSNSNS
 ≤30 mm678.0 ± 4.73.6 ± 2.16.4 ± 4.25.7 ± 2.73.8 ± 1.4
 >30 mm306.9 ± 4.03.4 ± 1.97.5 ± 7.25.2 ± 3.14.7 ± 2.6
mRNA levels
ERα99+0.125fNS−0.075NS+0.2430.015+0.187NS+0.008NS
(0.06)
ERβ 99−0.047NS+0.153NS+0.109NS+0.170NS+0.170NS
(0.09)(0.09)
PR99+0.2630.0083−0.002NS+0.192NS+0.3280.0011+0.135NS
(0.05)
CCND199+0.3280.0011+0.162NS+0.2580.0097+0.2720.0064+0.2950.0031
(0.10)
ERBB299+0.020NS+0.2540.011+0.153NS−0.109NS+0.05NS
(0.13)
  • a P, Kruskal-Wallis test for clinical and pathological parameters and Spearman rank correlation test for molecular mRNA levels.

  • b Case number.

  • c Mean mRNA levels ± SD.

  • d Scarff Bloom Richardson classification. Information available for 98 patients.

  • e Information available for 97 patients.

  • f Spearman correlation coefficient.